Home Page
Counties
Onondaga
13210
DUB THERAPEUTICS INC.

DUB THERAPEUTICS INC.

Company Details

Name:	DUB THERAPEUTICS INC.
Jurisdiction:	New York
Legal type:	FOREIGN BUSINESS CORPORATION
Status:	Active
Date of registration:	07 Sep 2023 (2 years ago)
Entity Number:	7157230
ZIP code:	13210
County:	Onondaga
Place of Formation:	Delaware
Foreign Legal Name:	DUB THERAPEUTICS INC.
Address:	505 irving avenue, room 3721, SYRACUSE, NY, United States, 13210

DOS Process Agent

Name	Role	Address
neuroscience research building	DOS Process Agent	505 irving avenue, room 3721, SYRACUSE, NY, United States, 13210

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Website:

www.dubtx.com

Phone Number:

540-313-1437

E-mail Address:

info@dubtx.com

Fax Number:

980-890-9977

Contact Person:

TERE WILLIAMS

Ownership and Self-Certifications:

Black American, Other Minority Owned, Women-Owned Small Business, Woman Owned

User ID:

P2892869

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:

RNZAEDZ7WJG2

CAGE Code:

9Z0D4

UEI Expiration Date:

2025-07-29

Business Information

URL:

www.dubtx.com

Activation Date:

2024-08-01

Initial Registration Date:

2022-08-12

History

Start date	End date	Type	Value
2024-01-17	2024-06-12	Address	841 east fayette street, SYRACUSE, NY, 13210, USA (Type of address: Service of Process)
2023-10-13	2024-01-17	Address	841 east fayette street, SYRACUSE, NY, 13210, USA (Type of address: Service of Process)

Filings

Filing Number	Date Filed	Type	Effective Date
240612001995	2024-06-12	CERTIFICATE OF CHANGE BY ENTITY	2024-06-12
240117001581	2024-01-16	CERTIFICATE OF AMENDMENT	2024-01-16
231013000338	2023-09-07	APPLICATION OF AUTHORITY	2023-09-07

USAspending Awards / Financial Assistance

Date:

2023-09-19

Link:

View on USAspending

Awarding Agency Name:

Department of Health and Human Services

Transaction Description:

A SINGLE DOSE ANTI-SCARRING THERAPEUTIC FOR THE CORNEA - ABSTRACT DUB BIOLOGICS IS DEVELOPING A THERAPEUTIC FOR THE PREVENTION AND TREATMENT OF CORNEAL SCARRING THROUGH KNOCKDOWN OF A NOVEL TARGET THAT HAS BEEN SHOWN TO BE CENTRAL TO THE FIBROTIC RESPONSE LEADING TO CORNEAL OPACIFICATION. CORNEAL OPACIFICATION SEVERELY IMPAIRS THE VISION OF 4.2 MILLION PEOPLE AROUND THE WORLD, 5.1% OF THE TOTAL BLIND POPULATION. MONOCULAR SCARRING IS FAR MORE COMMON, AFFECTING 3X AS MANY PEOPLE. SCARRING IN THE CORNEA RESULTING FROM INJURY, TRAUMA, OR INFECTION CAN LEAD TO DEBILITATING OPACITIES AND PERMANENT VISION LOSS. TREATMENTS TO PREVENT SCARRING INCLUDE CORTICOSTEROIDS HOWEVER, THEY HAVE UNPREDICTABLE RESULTS AND CAUSE WELL- ESTABLISHED ADVERSE EVENTS THAT INCLUDE CATARACTS AND GLAUCOMA. ONCE OPACIFICATION OCCURS, IT IS MOST OFTEN IRREVERSIBLE AND THE ONLY OPTION FOR PATIENTS ARE CORNEAL TRANSPLANTS. HOWEVER, ONLY 1 IN EVERY 80 CORNEAS NEEDED FOR TRANSPLANT ARE AVAILABLE. THEREFORE, PREVENTING OPACIFICATION IS OF UTMOST IMPORTANCE. DUB BIOLOGICS HAS IDENTIFIED A NOVEL SCARRING PATHWAY IN THE CORNEA, CENTRAL TO WHICH IS THE DEUBIQUITINASE USP10. USP10 ACTIVITY IN THE CORNEA FOLLOWING INJURY CAN BE MODULATED THROUGH KNOCKDOWN OF USP10 WITH A SELF-DELIVERY SIRNA (SDRNA). DUB BIOLOGICS’ DRUG IS A FULLY MODIFIED SDRNA CONJUGATED TO A CHOLESTEROL MOIETY THAT DOES NOT NEED ENCAPSULATION FOR DELIVERY. USP10-TARGETING SDRNA (SDUSP10) IS EFFECTIVELY DELIVERED TO THE CORNEA VIA EYE DROPS. ADDITIONALLY, SDUSP10 IS RESISTANT TO NUCLEASES, IS NOT IMMUNOGENIC, AND DEMONSTRATES IN VIVO EFFICACY FOR MONTHS AFTER A SINGLE TREATMENT. PREVIOUS WORK HAS FOCUSED ON MECHANISTIC STUDIES USING HUMAN PRIMARY CORNEAL STROMAL FIBROBLASTS, CORNEAL STROMAL WOUND HEALING MODELS IN MICE AND RABBITS, AND EX VIVO PIG ORGAN CULTURE. THIS DIRECT TO PHASE II SBIR PROJECT WILL ADVANCE SDUSP10 TOWARDS MARKET LAUNCH THROUGH EXPANSION OF EFFICACY STUDIES THAT WILL FOCUS ON PERSISTENCE EPITHELIAL DEFECT (PED) MODELS IN MICE AND RABBITS AND IN HUMAN CORNEAL ORGAN CULTURE. BASED ON COMPARABLE THERAPEUTICS IN THE OCULAR SPACE, THESE WILL CONTRIBUTE SIGNIFICANTLY TO THE ANIMAL EFFICACY STUDIES NEEDED BEFORE FIRST-IN-HUMAN TRIALS. IN PREPARATION FOR IND FILING, THE PROJECT WILL ALSO SUPPORT THE DEMONSTRATION OF SCALED-UP PRODUCTION OF HUMAN SDUSP10 IN A GLP ENVIRONMENT. THE PRODUCTION RUNS WILL BE USED TO CONDUCT IND-ENABLING STUDIES INCLUDING TOXICOLOGY AND PK EXPERIMENTS IN RABBITS. AT THE CONCLUSION OF THE PROJECT, DUB BIOLOGICS WILL HAVE COMPLETED ALL REQUIRED EFFICACY STUDIES, CREATED A SCALED- UP MANUFACTURING PROCESS THAT IS READY FOR CGMP CONVERSION, AND DEMONSTRATED THE SAFETY PROFILE OF SDUSP10. THIS WILL VALIDATE THE TECHNICAL VIABILITY OF PURSUING THIS THERAPEUTIC PIPELINE, ENABLING EXTERNAL INVESTMENT TO FUND THE REMAINING IND-ENABLING STUDIES AND CONDUCT EARLY-STAGE CLINICAL TRIALS. CREATING A WAY TO PREVENT PED AND CORNEAL SCARRING SAFELY AND EFFECTIVELY WILL IMPROVE THE QUALITY OF LIFE OF MILLIONS OF PATIENTS AROUND THE WORLD AND REDUCE THE ECONOMIC BURDEN OF CORNEAL OPACIFICATION AND DEMAND FOR CORNEAL TRANSPLANTS.

Obligated Amount:

1799926.00

Face Value Of Loan:

0.00

Total Face Value Of Loan: